Scil Proteins Appoints Advisory Board
Scil Proteins announced that it has completed the Formation of its advisory board (AB). The AB is comprised of Dr. Andreas Menrad, Dr. Jürgen Wahl and Rainer Kroell.
Andreas Menrad, PhD, is currently the Vice President of Antibody Therapeutics at Genzyme’s European Research site in Cambridge, UK. Prior to this, he was Genzyme’s Director of Research and Development. Dr. Menrad has extensive experience in the fields of experimental dermatology, inflammation and oncology as well as antibody engineering, having held positions as Project Team Leader and Director of Antibody Engineering and Anti-Angiogenesis Research at Schering AG. Dr. Menrad graduated from the University of Stuttgart and conducted his PhD at the Max-Planck Institute. In addition, he was a post-doctoral fellow at the Wistar Institute in Philadelphia, Pennsylvania.
Jürgen Wahl, PhD, is the former head of biotech production at Roche in Penzberg, Germany. In his 22 years at Roche, Dr. Wahl’s activities focused on the fermentation of microorganisms for enzyme production and setting up the mammalian cell culture unit for Epoetin beta, as well as diagnostic and therapeutic antibodies. As Head of Biotech Production, he was also responsible for the development and production of various therapeutic drug substances. Dr. Wahl earned degrees in biochemistry, biology and pharmacy from the University of Tübingen.
Dr. Menrad will be responsible for advising the Pharma business unit of Scil Proteins, focusing on the Affilin® technology and Affilin® product development, while Dr. Wahl will advise the recombinant protein production business unit, focusing on process development and GMP manufacturing.
Rainer Kroell holds a diploma in business studies from the University of Passau and gained his specific qualification as tax advisor in 1997 and his certification as an auditor in 2000. In 1999, he co-founded GKK Partners and is now Senior Partner of this recognized and well-known company for tax consultation and auditing in Munich, Germany. Mr. Kroell has also a focus on biotechnology and he supports Scil Proteins in various financial and taxation issues.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
